FDA
approval
· 2022-09-08
FDA Approved: ADAKVEO — Supplemental Application (Novartis Pharmaceuticals Corporation)
Summary
The FDA approved a supplemental application for ADAKVEO (crizanlizumab) submitted by Novartis Pharmaceuticals Corporation, potentially expanding or updating the…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for ADAKVEO (CRIZANLIZUMAB)